Industry: Cancer therapeutics
SIRPant is pioneering an adoptive cell therapy to treat cancer, circumventing regular activity of the cancer microenvironment to activate phagocytes, which eat cancer cells and can induce long-lasting cancer immunity.
This macrophage-based technology (SIRPant-M), the company’s lead candidate, has been extensively vetted in mice, where it has rapidly eliminated metastatic solid tumors, induced anti-cancer immunity and brought an overall survival rate of 100% for treated mice.
The procedure involves a simple blood draw, treatment of isolated cells and grafting of treated cells back into the patient. It is much simpler than existing viral infection or genetic reprogramming therapies for cancer treatment.
In phase IIB, studies will refine SIRPant-M and test cytotoxicity. This treatment could address the needs of patients for whom conventional therapies are ineffective.
The types of cancer treated in the mouse trials include pancreatic adenocarcinoma, colorectal carcinoma, metastatic melanoma, lymphoma, non-small cell lung cancer and breast cancer.
Company website: SIRPant Immunotherapeutics